![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
CLINICAL PHARMACOLOGY OF CIPROFLOXACIN IN INFANTS AND CHILDREN
Prof. Gian Maria Pacifici*
ABSTRACT
Ciprofloxacin is a fluoroquinolone and targets bacterial DNA gyrase and topoisomerase IV. For many gram-positive bacteria topoisomerase IV is the primary target. In contrast, DNA gyrase is the primary quinolone target for many gram-negative bacteria. Ciprofloxacin inhibits gyrase-mediated DNA supercoiling at concentrations that correlate with those required to inhibit bacterial growth (0.1 to 10 μg/ml). Ciprofloxacin is active against Proteus, Escherichia coli, Klebsiella, Salmonella, Shigella, Enterobacter, Campylobacter, Chlamydia, Mycoplasma, Legionella, Brucella, Mycobacterium tuberculosis, Mycobacterium fortuitum, and Mycobacterium kansasii. Ciprofloxacin is rapidly absorbed following oral administration and the mean elimination half-life of ciprofloxacin is 16.6, 6.2, 4.2, and 3.3 Keywords: milk, cerebrospinal-fluid, ciprofloxacin, dosing, efficacy-safely, drug-interaction, meningitis, pharmacokinetics, placenta, prophylaxis, and treatment. [Download Article] [Download Certifiate] |